Bioverativ Inc (NASDAQ:BIVV) Stake Increased by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC grew its position in shares of Bioverativ Inc (NASDAQ:BIVV) by 40.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 131,579 shares of the biotechnology company’s stock after buying an additional 37,667 shares during the quarter. Gateway Investment Advisers LLC owned 0.12% of Bioverativ worth $7,095,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of BIVV. Advisors Asset Management Inc. bought a new position in Bioverativ during the third quarter valued at approximately $137,000. TCI Wealth Advisors Inc. bought a new position in Bioverativ during the third quarter valued at approximately $186,000. Ladenburg Thalmann Financial Services Inc. bought a new position in Bioverativ during the third quarter valued at approximately $190,000. Canada Pension Plan Investment Board bought a new position in Bioverativ during the third quarter valued at approximately $194,000. Finally, ACG Wealth bought a new position in Bioverativ during the third quarter valued at approximately $205,000. Hedge funds and other institutional investors own 94.10% of the company’s stock.

Several research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a research report on Monday, January 8th. Jefferies Group increased their price target on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday, January 18th. Raymond James Financial downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Credit Suisse Group reiterated a “neutral” rating and issued a $65.00 price target on shares of Bioverativ in a research report on Thursday, January 18th. Finally, Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Thirteen investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Bioverativ presently has a consensus rating of “Hold” and an average target price of $63.15.

Shares of Bioverativ Inc (NASDAQ BIVV) traded up $0.55 during mid-day trading on Monday, hitting $103.60. 1,583,475 shares of the stock traded hands, compared to its average volume of 3,320,539. Bioverativ Inc has a 12-month low of $43.19 and a 12-month high of $104.30.

TRADEMARK VIOLATION WARNING: “Bioverativ Inc (NASDAQ:BIVV) Stake Increased by Gateway Investment Advisers LLC” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/12/gateway-investment-advisers-llc-raises-holdings-in-bioverativ-inc-bivv-updated-updated-updated.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply